Raw data for: Acupoint Plaster Application Combined with Omalizumab for Severe Allergic Asthma: A Randomized Controlled Trial

This dataset contains de-identified patient-level data from a prospective, randomized, open-label, parallel-group clinical trial conducted between June 2024 and December 2024 at Chengdu Integrated Traditional Chinese Medicine and Western Medicine Hospital, China. A total of 56 adults with severe allergic asthma were randomized 1:1 to receive either omalizumab plus acupoint plaster application (experimental group, n=28) or omalizumab alone (control group, n=28). The dataset includes baseline demographic and clinical characteristics, co-primary outcomes (Asthma Control Test score and Traditional Chinese Medicine symptom score), secondary outcomes (Mini Asthma Quality of Life Questionnaire, rescue medication use, peripheral blood eosinophil count, fractional exhaled nitric oxide, pulmonary function parameters, and T-lymphocyte subsets) measured at baseline, week 8, and week 16, as well as adverse event records. All data have been de-identified in accordance with applicable privacy regulations.